potent, selective CECR2 bromodomain inh.
cell permeable tool compound
from HTS + SBDD on ATAD2, CECR2 model
J. Med. Chem., May 28, 2020
GlaxoSmithKline, Stevenage, UK
GSK232 is a highly selective cell-penetrant inhibitor of the non-BET CECR2 bromodomain with >500-fold selectivity over BET-family bromodomains identified during a campaign to find selective inhibitors of the bromodomain…